GLP1R and neoplasm: Although more comprehensive clinical trials are necessary to establish safety, efficacy, and optimal dosing strategies in oncological settings, the data thus far indicate that GLP-1 receptor agonists do not exacerbate tumour growth and may counteract it through multiple molecular mechanisms.